Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New antibody drug takes aim at Hard-to-Treat cancers

NCT ID NCT06380816

First seen May 08, 2026 · Last updated May 23, 2026 · Updated 4 times

Summary

This trial tests a new drug called UCB4594, an antibody that targets a protein (HLA-G) found on many cancer cells. The goal is to see if it helps the immune system attack tumors. It is for people with advanced solid tumors (like lung, breast, or colon cancer) that have not responded to standard treatments. The study will find the safest dose, check side effects, and see if the drug can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guy's Hopsital

    RECRUITING

    London, SE1 9RT, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Christie NHS Foundation Trust

    RECRUITING

    Manchester, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

    RECRUITING

    Newcastle upon Tyne, NE7 7DN, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital Southampton NHS Foundation Trust

    NOT_YET_RECRUITING

    Southampton, United Kingdom

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.